DELTA FORCE: Delgocitinib Cream Superior for Chronic Hand Eczema Treatment
New data from the DELTA FORCE trial presented at the 33rd European Academy of Dermatology and Venereology (EADV) Congress suggests that delgocitinib cream showed superior efficacy and safety compared to oral alitretinoin for the treatment of chronic hand eczema (CHE).
“The completion of the DELTA FORCE study marks a significant milestone in our understanding of moderate to severe chronic hand eczema treatment,” said Kreesten Meldgaard Madsen, Chief Development Officer at LEO Pharma, said in a press release. “With the full results now available, we have gained a new understanding of how topical treatment with delgocitinib cream compares to alitretinoin.”
The manufacturer revealed late-breaking data from the DELTA FORCE phase 3 trial in a pre-conference news release. the trial program compared delgocitinib cream to oral alitretinoin (the only other approved treatment for severe CHE in Europe). According to the data shared, delgocitinib cream achieved a greater reduction in Hand Eczema Severity Index (HECSI) scores over 12 weeks [mean decrease of 67.6 vs. alitretinoin’s 51.5, (P < 0.001)]. Additionally, 27.2% of patients on delgocitinib achieved Investigator’s Global Assessment treatment success vs. 16.6% with alitretinoin (P = 0.004).
Delgocitinib cream also presented a better safety profile, with fewer treatment-emergent adverse events reported in patients using the topical therapy (49.4%) compared to alitretinoin (76.1%).
“Alongside the results of DELTA FORCE, an extensive body of work, encompassing clinical trial data, real-world findings from both clinicians and patients, and a detailed biopsy analysis provides a multifaceted view of CHE and its treatment landscape,” said Alexander Egeberg, Head of Global Medical Affairs, LEO Pharma. “This data not only enhances our knowledge of CHE management but also potentially paves the way for a new topical option in clinicians’ therapeutic arsenal.”
Source: LEO Pharma press release. Sept 26, 2024.